MedPath

A Study to Evaluate the Safety and Effectiveness Transdermal Compress Device in Participants with Transfemoral Amputations

Phase 3
Recruiting
Conditions
Prosthesis and Implants
Interventions
Device: Transdermal Compress Device
Registration Number
NCT06134167
Lead Sponsor
Balmoral Medical company
Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the Transdermal Compress device in participants with Transfemoral Amputations.

Detailed Description

This study is a prospective, multicenter, single-arm, open-label study in skeletally mature participants with transfemoral limb loss (unilateral or bilateral), without bone or vascular disease who have or are anticipated to have rehabilitation problems with or cannot use a conventional socket prosthesis.

Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1.

Participant progression including clinical assessments and prosthetic use will follow the study rehabilitation protocol.

Events of special interest include superficial and deep infections at the implant site, failures, and secondary surgical interventions; participants will be followed for all soft tissue interface issues.

Participants will be assessed for effectiveness and safety endpoints at baseline and at Months 6, 12, 18, and 24 and annually through 5 years post-implantation.

Adverse events and adverse device effects will be collected and reported starting at the time of surgical implantation.

Study participants will also be included in the Osseointegration Quality Registry in parallel to this study to allow for long-term follow-up post-study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Transdermal Compress DeviceTransdermal Compress DeviceThe Transdermal Compress device is a bone-anchored transdermal implant that addresses the shortcomings of a socket prosthesis and provides options to amputees who are not able to utilize a conventional socket prosthesis.
Primary Outcome Measures
NameTimeMethod
The study primary endpoint is a composite endpoint to determine the proportion of participants who are successful on the primary effectiveness and safety endpoints (overall success) at 2 yearsTwo (2) years post-implantation

The following endpoint components will be used to assess effectiveness in the composite endpoint:

Prosthetic Wear Time PROMIS Physical Function OPUS Satisfaction with Devices and Services

The following will be used to assess safety in the composite endpoint:

Lack of secondary surgical intervention. No more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.

Radiographic success.

Secondary Outcome Measures
NameTimeMethod
Patient Reported Outcome Measurement Information System: Pain IntensityTwo (2) and Five (5) years post-implantation

Pain Intensity domain measures self-reported pain on a scale of 0 (No Pain) to 10 (Worst imaginable pain).

Patient Reported Outcome Measurement Information System: Pain InterferenceTwo (2) and Five (5) years post-implantation

They include observable displays (sighing, crying), pain severity behaviors (resting, guarding, facial expressions, and asking for help), and verbal reports of pain. The scale contains 7-question rating to evaluate pain behavior on a 6 point scale (1 = Had no pain, 6 = Always have pain

Orthotics and Prosthetics Users Survey: Satisfaction with DevicesTwo and Five (2-5) years post-implantation

21-item scale that measures satisfaction with the prosthetic device and care quality. Items are rated on 5 points (1 = Strongly agree to 5 = Strongly Disagree).

A composite endpoint will be evaluated to determine the proportion of participants who are successes on both the primary effectiveness and safety endpoints at 2 years and 5 years.Two (2) and Five (5) years post-implantation

The following endpoint components will be used to assess effectiveness in the composite endpoint:

Prosthetic Wear Time Patient Reported Outcome Measurement Information System: Physical Function Orthotics and Prosthetics Users Survey: Satisfaction with Devices

Type and frequency of mechanical complications over time.Two (2) and Five (5) years post-implantation

Any mechanical complications will be recorded and evaluated for device deficiencies.

Patient Reported Outcome Measurement Information System: Pain BehaviorTwo (2) and Five (5) years post-implantation

Measures self-reported external manifestations of pain: behaviors that typically indicate to others that an individual is experiencing pain.

Lack of secondary surgical interventionTwo (2) and Five (5) years post-implantation

Lack of secondary surgical intervention

Prosthetic Wear TimeTwo (2) and Five (5) years post-implantation

Prosthetic Wear Time- Hours per Day.

Patient Reported Outcome Measurement Information System: Physical FunctionTwo (2) and Five (5) years post-implantation

Clinical outcome assessment (COA) that measures the patient's experience with the use of a transdermal device in that the primary goal is to improve physical function.: Physical Function. Items on are rated on 5 points (1 = unable to do. 5 = Without any difficulty).

Overall infection rateTwo (2) and Five (5) years post-implantation

Overall infection rate subclassified as deep or superficial to the fascia.

The proportion of participants with no more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.Two (2) years post-implantation

The proportion of participants with no more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.

The proportion of participants who have had serious device-related adverse events.Two (2) and Five (5) years post-implantation

The proportion of participants who have had serious device-related adverse events.

Trial Locations

Locations (9)

UC Davis Medical Center

🇺🇸

Sacramento, California, United States

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

Walter Reed Military Medical Center

🇺🇸

Washington, District of Columbia, United States

Northwestern Memorial Hospital

🇺🇸

Chicago, Illinois, United States

The Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

The Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

Penn Medicine; University of Pennsylvania Health System

🇺🇸

Philidelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburg, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath